Microbes and Metabolites Fuel an Ambitious Aging Project
Last week, genomics entrepreneur Craig Venter announced his latest venture: a company that will create what it calls the most comprehensive and complete data set on human health to tackle diseases of aging.Human Longevity, based in San Diego, says it will sequence some 40,000 human genomes per year to start.
They will useIllumina’s new high-throughput sequencing machines (see “Does Illumina Have the First $1,000 Genome?”). Eventually, it plans to work its way up to 100,000 genomes per year.
The company will also sequence the genomes of the body’s multitudes of microbial inhabitants, called the microbiome, and analyze the thousands of metabolites that can be found in blood and other patient samples.
By combining these disparate types of data, the new company hopes to make inroads into the enigmatic process of aging and the many diseases, including cancer and heart disease, that are strongly associated with it.
“Aging is exerting a force on humans that is exposing us to diseases, and the diseases are idiosyncratic, partly based on genetics, partly on environment,” says Leonard Guarente, who researches aging at MIT and is not involved in the company. “The hope for many of us who study aging is that by having interventions that hit key pathways in aging, we can affect disease.”
But despite decades of research on aging and age-related diseases, there are no treatments to slow aging, and diseases like cancer, heart disease, and Alzheimer’s continue to plague patients.
A more comprehensive approach to studying human aging could help, says Guarente. The key is to go beyond genome sequencing by looking at gene activity and changes in the array of proteins and other molecules found in patient samples.
To that end, Human Longevity will collaborate with Metabolon, a company based in Durham, North Carolina, to profile the metabolites circulating in the bloodstreams of study participants. Metabolon was an early pioneer in the field of metabolomics, which catalogues the amino acids, fats, and other small molecules in a blood or other sample to develop more accurate diagnostic tests for diseases